Sign in
Taking peopleNo phase

Neurofeedback-Based Digital Therapeutics for the Diagnosis and Treatment of ADHD in Children.

Key facts

Who runs it
Lei Lei, MD
Where
China2 sites in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
210 people, planned
Started
24 Feb 2023
Planned end
31 Dec 2025
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Concerta
  • Digital therapeutics
Record updated
10 June 2025

Who can take part

Age
6 years to 12 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Meet the diagnostic criteria established by the 5th edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) for ADHD
  • Digital Cancellation Test total score<50 points
  • Raven's Standard Progressive Matrices score≥85
  • 6 years ≤ Age<12 years
  • No interventions for ADHD received within 4 weeks
  • No color blindness

Who cannot take part

  • Patients with organic mental disorders, schizophrenia, bipolar disorder, depressive disorders, and other psychiatric conditions
  • Patients with comorbid autism spectrum disorder, Tourette's syndrome, and other neurodevelopmental disorders
  • Patients with comorbid conduct disorders
  • Patients with severe traumatic brain injury or neurological disorders
  • Patients with a history of severe somatic diseases
  • Patients with a history of substance or drug dependency

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 6 and 12 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

A multi-center, randomized controlled trial is being conducted to investigate the efficacy of a novel digital therapeutics (DTx) program that utilizes a cross-training approach between neurofeedback training and executive function training for pediatric patients (aged 6-12) diagnosed with ADHD. This gamified interactive program is designed to improve attention deficits and executive function impairments in pediatric patients with ADHD. It is delivered through an engaging iPad game in a home-based treatment format. Patients will be randomly assigned to one of three groups: medication alone, digital therapeutics alone, or a combination of both interventions. Subjects will undergo 30 treatment sessions over the 8-week period, with each session lasting 30 minutes. Investigators will reassess symptoms of ADHD, executive functions, and objective measures of attention at the end of the treatment. Additionally, questionnaires will be distributed to parents to gather their insights and feedback on the treatment approach. This innovative digital therapeutics approach is expected to improve ADHD symptoms individually and enhance therapeutic outcomes when used alongside conventional drug treatment regimens.

The 3 groups in the trial

  • Medication groupExisting treatment, for comparison

    The medication group will take Methylphenidate Hydrochloride Extended-Release Tablets with a fixed dose for eight weeks.

    Treatment: Concerta

  • Digital therapeutics groupTreatment being tested

    The digital therapeutics group will complete 30 training sessions within 8 weeks.

    Treatment: Digital therapeutics

  • Combination groupTreatment being tested

    The combination group will take Methylphenidate Hydrochloride Extended-Release Tablets while undergoing digital therapeutics.

    Treatment: Concerta and Digital therapeutics

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Neurofeedback-Based Digital Therapeutics for the Diagnosis and Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Children.
Criteria questions
Built from NCT06369714, who can take part
Publications
Record updated
10 June 2025